Last €2.25 EUR
Change Today 0.00 / 0.00%
Volume 0.0
NB1 On Other Exchanges
Symbol
Exchange
Frankfurt
As of 2:16 AM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

biota pharmaceuticals inc (NB1) Snapshot

Open
€2.22
Previous Close
€2.25
Day High
€2.25
Day Low
€2.18
52 Week High
03/5/14 - €5.06
52 Week Low
06/6/14 - €1.67
Market Cap
79.0M
Average Volume 10 Days
15.0
EPS TTM
--
Shares Outstanding
35.1M
EX-Date
11/9/12
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOTA PHARMACEUTICALS INC (NB1)

Related News

No related news articles were found.

biota pharmaceuticals inc (NB1) Related Businessweek News

No Related Businessweek News Found

biota pharmaceuticals inc (NB1) Details

Biota Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of anti-infective products in Australia. The company is developing oral, small molecule compounds to treat various viral and bacterial infections. Its product candidates include laninamivir octanoate, a long-acting neuraminidase inhibitor, which is in Phase II clinical trials for the treatment of influenza A and B; vapendavir, a Phase II compound that is in clinical development for the treatment of human rhinovirus infections in patients with mild to moderate asthma; and a discovery stage program focused on novel antibiotics to treat gram-positive and gram-negative bacterial infections. It is also developing an orally bioavailable preclinical compound for the treatment of respiratory syncytial virus infections in children, the elderly, and immunocompromised patients. Biota Pharmaceuticals, Inc. is headquartered in Alpharetta, Georgia.

89 Employees
Last Reported Date: 09/27/13

biota pharmaceuticals inc (NB1) Top Compensated Officers

Chief Executive Officer, President, Principal...
Total Annual Compensation: $395.2K
Executive Vice President of Corporate Develop...
Total Annual Compensation: $292.9K
Vice President of Human Resources
Total Annual Compensation: A$237.9K
Vice President of Research
Total Annual Compensation: A$332.3K
Vice President of Product Development and Str...
Total Annual Compensation: A$312.4K
Compensation as of Fiscal Year 2013.

biota pharmaceuticals inc (NB1) Key Developments

Biota Pharmaceuticals, Inc. Announces Restructuring Plan

Biota Pharmaceuticals, Inc. announced that following the completion of an operational review of the company, its Board of Directors has adopted a plan to restructure the company's operations. The adoption of the plan was the result of a recent decision by the Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response (ASPR) Biomedical Advanced Research and Development Authority (BARDA) to terminate its contract with the company for the convenience of the U.S. Government. This contract was supporting the development of laninamivir octanoate, a long-acting neuraminidase inhibitor (LANI), for the treatment of uncomplicated influenza A and B. Immediate actions resulting from the adoption of this plan will involve a re-alignment of the company's operations and resources. Specifically, the company plans to reduce its workforce by approximately two-thirds over the next six to nine months and close its Melbourne, Australia facility by June 30, 2015. The company anticipates recording an estimated total charge of approximately $5.0 - $5.5 million over this and the next several quarters in association with this restructuring plan. Upon expected completion of the plan in the first half of 2015, the company estimates its annual, ongoing research and development and general and administrative overhead costs will be reduced by approximately $8.0 - $10.0 million from current annualized levels. In the near-term the company intends to focus its efforts on its late-stage clinical assets, namely LANI and vapendavir, as well as preclinical compounds being developed for the treatment of respiratory syncytial infections (RSV). The company anticipates data that will inform on the possible next steps in the development of each of these respective programs will be available in the third quarter. Further, the company anticipates exploring alternative business development and/or financing arrangements that could facilitate the continued development of LANI in later-stage clinical trials.

Biota Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Biota Pharmaceuticals, Inc. reported earnings results for the third quarter and nine months ended March 31, 2014. Net income for the third quarter was $3.2 million, or $0.09 per share, compared to $200,000, or $0.01 per share, for the same quarter ended March 31, 2013. Total revenue for the third quarter ended March 31, 2014 was $29.5 million, compared to $12.5 million for the same quarter ended March 31, 2013. Net loss for the nine months ended March 31, 2014 was $800,000, or $0.03 loss per share, compared to a net loss of $2.4 million, or $0.09 loss per share, for the same period ended March 31, 2013. Total revenue for the nine months ended March 31, 2014 was $60.3 million, compared to $24.3 million for the same period ended March 31, 2013.

Biota Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 08:00 AM

Biota Pharmaceuticals, Inc. Presents at Jefferies 2014 Global Healthcare Conference, Jun-02-2014 08:00 AM. Venue: Grand Hyatt, New York, New York, United States. Speakers: Joseph M. Patti, Executive Vice President of Corporate Development & Strategy and Assistant Secretary.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NB1:GR €2.25 EUR 0.00

NB1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Roche Holding AG SFr.268.30 CHF +1.80
View Industry Companies
 

Industry Analysis

NB1

Industry Average

Valuation NB1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.5x
Price/Book 1.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOTA PHARMACEUTICALS INC, please visit www.biota.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.